Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|FGFR2 amp||stomach cancer||predicted - sensitive||Futibatinib||Phase I||Actionable||In a Phase I trial, Futibatinib (TAS-120) treatment resulted in clinical response in a gastric cancer patient harboring FGFR2 amplification (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 372PD).||detail...|
|FGFR2 amp||stomach cancer||predicted - sensitive||Futibatinib||Case Reports/Case Series||Actionable||In a Phase I trial, Futibatinib (TAS-120) treatment led to an overall objective response rate of 22% (2/9, 2 partial responses) and a disease control rate of 55.6% (5/9) in patients with gastric cancer harboring an FGFR2 amplification or FGFR3 rearrangement, including a progression-free survival of 4.8 months and a duration of response of 3.5 months in a patient with FGFR2 amplification (PMID: 34551969; NCT02052778).||34551969|
|FGFR2 amp||stomach cancer||predicted - sensitive||Futibatinib||Case Reports/Case Series||Actionable||In a Phase I trial, Futibatinib (TAS-120) treatment resulted in a partial response in 2 patients with gastric cancer harboring FGFR2 amplification, with 59% and 90% tumor shrinkage, respectively (Annals of Oncology (2020) 31 (suppl_4): S475).||detail...|
|FGFR2 amp||stomach cancer||predicted - sensitive||Futibatinib||Preclinical - Cell culture||Actionable||In a preclinical study, Futibatinib (TAS-120) treatment inhibited growth of gastric cancer cells harboring FGFR2 amplification in culture (PMID: 33563752).||33563752|
|PubMed Id||Reference Title||Details|
|First-in-human (FIH) study of TAS-120, a highly selective covalent oral fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced solid tumors||Full reference...|
|Phase I study of the irreversible FGFR inhibitor (i) futibatinib (FBN; TAS-120) in Japanese patients (pts) with advanced (adv) solid tumours||Full reference...|
|(33563752)||Rapid Resistance of FGFR-driven Gastric Cancers to Regorafenib and Targeted FGFR Inhibitors can be Overcome by Parallel Inhibition of MEK.||Full reference...|
|(34551969)||Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study.||Full reference...|